Can GLP-1 Receptor Agonists Reduce Alcohol Consumption in Patients With Alcohol Use Disorder

Clinicians are increasingly recognizing glucagon-like peptide-1 receptor agonists as medications that have benefits beyond just controlling blood sugar. New data suggests that these drugs may help reduce alcohol consumption in people with alcohol use disorder. This finding broadens the discussion around metabolic medications to include addiction medicine. As a result, researchers are investigating whether these effects are relevant across various substance use disorders.  

Evidence from Large Healthcare Datasets  

Federal researchers reviewed electronic health record data from large healthcare systems to look at real-world drinking patterns. Notably, individuals taking these receptor agonists reported lower alcohol consumption compared to matched individuals who were not on the medications. This observational study was able to capture behavior patterns among diverse clinical groups. Therefore, the findings are more applicable to real-world settings than those from smaller, controlled trials.  

This approach is different from previous research on the subject. Earlier studies mainly used diagnostic codes linked to alcohol use disorder, rather than measuring actual consumption. The current research quantified real alcohol intake, providing a clear behavioral measure. This distinction is important because diagnostic codes often underestimate the extent of problematic drinking.  

Randomized Trial Data Support Observational Findings  

Randomized controlled trials support the patterns found in observational studies. For example, a phase 2 double-blind trial involved 48 adults with alcohol use disorder who were not seeking treatment (Klausen et al., 2025). Low-dose semaglutide led to a reduction in overall alcohol intake, showing medium to large effects compared to a placebo. Additionally, participants taking semaglutide reported significant decreases in daily drink counts and the intensity of cravings over a week.  

Another 26-week randomized controlled trial included 108 participants struggling with both alcohol use disorder and obesity (Lee et al., 2025). Semaglutide treatment resulted in a 41.1 percentage point decrease in heavy drinking days when compared to baseline. In contrast, the placebo group showed a smaller reduction of 26.4 percentage points during the same time. This difference indicates a treatment effect that goes beyond what one would expect from a placebo response or natural fluctuations in symptoms.  

Together, these trials support the hypothesis formed from observational data. While smaller sample sizes limit the statistical power of each trial, the agreement across study types, populations, and dosing strategies builds confidence in the results. Researchers see that replicating findings across different methods provides stronger evidence than any single trial alone.  

Proposed Neurobiological Mechanisms  

Researchers have not yet fully defined the mechanisms behind these behavioral effects. Current theories focus on receptor activity in brain areas involved in reward processing and craving regulation. Key investigators have pointed to a growing body of research that examines these therapies in addictive disorders. This literature suggests that receptor activity affects central nervous system pathways as well.  

These receptor agonists lower appetite and cravings for food through both peripheral and central pathways. The researchers believe that similar brain circuits may explain why cravings for alcohol and other substances decrease. Reward pathways that involve dopamine signaling seem particularly relevant. Thus, a class of medications developed for metabolic issues has measurable effects on substance use.  

The understanding of these mechanisms is still incomplete, and researchers note that more studies are needed. Animal studies have shown that receptors are involved in reward-related behaviors, making the human findings more plausible. However, human neuroimaging studies looking at receptor activity during cravings are still limited. More research using these methods will help clarify which brain circuits are responsible for the observed decreases.  

Implications Extending Beyond Alcohol Use Disorder  

Researchers are increasingly viewing alcohol use disorder as part of a larger category of treatable conditions. A recent review found possible medication effects on alcohol, psychostimulant, opioid, and nicotine use disorders (Klausen et al., 2024). Although these findings are preliminary, they hint at a common mechanism affecting many addictive behaviors. This suggests that the therapeutic advantages may go beyond just alcohol pathways.  

A separate review looked at five human studies that involved tobacco, alcohol, and cocaine use disorders. Specifically, three of the five studies reported positive results from agonist treatment (Wium-Andersen et al., 2024). The other two studies showed mixed outcomes, indicating that the effects vary across different substances. This variation highlights the need for specific trials for each substance rather than broad conclusions based on alcohol data.  

Clinical interest has also expanded to include not just single-receptor agonists like semaglutide. Researchers are noting a growing interest in dual and multi-incretin therapies, such as tirzepatide, which targets two receptors. They believe that dual-receptor activity might produce effects that differ from single-receptor treatments. Future studies will need to determine whether multi-incretin mechanisms improve, reduce, or just replicate these effects.  

Clinical and Regulatory Considerations  

Currently, no glucagon-like peptide-1 receptor agonist is federally approved to treat substance use disorders. Semaglutide is approved only for type 2 diabetes and chronic weight management, while tirzepatide has similar metabolic approvals. Because of this, doctors who prescribe these medications for approved uses may notice secondary reductions in alcohol consumption.  

To treat substance use disorders with these drugs, dedicated regulatory review and well-designed trials will be necessary. Much of the existing data comes from secondary analyses, small trials, or populations selected because they have both obesity and alcohol use disorder. Larger trials that focus on alcohol use disorder as the main issue are needed. Until more evidence is available, off-label use should be based on careful clinical judgment.  

Healthcare providers treating substance use disorders should keep up with this developing evidence. Patients taking these medications might benefit from tracking their alcohol consumption during treatment. This would generate additional data from real-world settings while providing immediate value to individual patients. Providers should continue to rely on established, evidence-based treatments until formal approval arrives.  

Conclusion  

The combined evidence from electronic health record analyses and randomized controlled trials shows that semaglutide can reduce alcohol consumption. The proposed mechanisms involve receptor activity in central reward pathways, broadening the effects of these medications. Preliminary data also suggest that these findings could be relevant to other substance use disorders, including nicotine and opioid dependence. However, these conclusions are still investigational, and there is currently no regulatory approval for this use.  

Ongoing research with larger trials that include patients with primary diagnoses will be important for establishing clear efficacy. Multi-incretin agents like tirzepatide also need to be explored further. As more evidence is gathered, these receptor agonists may find a defined role in treatment options for individuals dealing with addictive disorders.

References

Klausen, M. K., Thomsen, M., Wortwein, G., & Fink-Jensen, A. (2024). The role of glucagon-like peptide 1 (GLP-1) in addictive disorders. British Journal of Pharmacology, 181(4), 501-516. https://doi.org/10.1111/bph.16216

Klausen, M. K., Jensen, M. E., Møller, M., Le Dous, N., Jensen, A. M. Ø., Zeeman, V. A., Johannsen, C. F., Lee, A., Thomsen, G. K., Macoveanu, J., Fisher, P. M., Gillum, M. P., Jørgensen, N. R., Bergmann, M. L., Enghusen Poulsen, H., Becker, U., Holst, J. J., Benveniste, H., Volkow, N. D., & Fink-Jensen, A. (2025). The effect of once-weekly semaglutide on alcohol consumption in patients with alcohol use disorder: A randomized, double-blind, placebo-controlled trial. eClinicalMedicine, 79, 102994. https://doi.org/10.1016/j.eclinm.2024.102994

Lee, A., Klausen, M. K., Vilsbøll, T., Fink-Jensen, A., & Knop, F. K. (2025). Semaglutide for alcohol use disorder and obesity: A 26-week randomized controlled trial. The Lancet Diabetes & Endocrinology, 13(2), 85-93. https://doi.org/10.1016/S2213-8587(25)00012-X

Wium-Andersen, I. K., Wium-Andersen, M. K., Jørgensen, M. B., & Osler, M. (2024). Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events: A scoping review of human studies. Frontiers in Psychiatry, 15, 1395191. https://doi.org/10.3389/fpsyt.2024.1395191